Pathogenesis and inflammaging in MDS [MDS Professional Report]

Treatment of lower-risk MDS [MDS Professional Report]

Treatment for Higher-risk MDS [MDS Professional Report]

Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]

New trials to address the anemia of lower-risk MDS [MDS Professional Report]

Transfusions and quality of life [MDS Professional Report]

Bone marrow failure disorders in childhood [MDS Professional Report]

The role of genetics in MDS management [MDS Professional Report]

MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]

Do immune check inhibitors have a role in the treatment of higher-risk MDS? [MDS Professional Report]

Will Venetoclax Become The New Standard? [MDS Professional Report]

Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report]

TP53 mutations – were they born equal [MDS Professional Report]

EHA 2025 updates [MDS Professional Report]